Retatrutide: The Next Generation
of GLP-1 Weight Loss
The most powerful weight loss drug in clinical trials. 24% average weight loss in 48 weeks—beating semaglutide and tirzepatide. Join the waitlist to be notified when it launches.
Join 10,000+ People on the Waitlist
Be first to know when retatrutide becomes available—plus get exclusive early access pricing and updates from Phase 3 trials.
How Retatrutide Works
Retatrutide is a triple-agonist drug that activates three receptors: GLP-1, GIP, and glucagon. This combination delivers more weight loss than any FDA-approved medication.
Triple-Receptor Action
Targets GLP-1 (appetite), GIP (insulin), and glucagon (metabolism) for maximum fat burning.
Proven in Trials
Phase 3 data shows 24% weight loss vs 22% for tirzepatide—the current gold standard.
Once-Weekly Injection
Same convenience as Wegovy or Zepbound—just one subcutaneous injection per week.
Beyond Weight Loss
Also shows benefits for fatty liver (80% reduction), knee pain, and metabolic health.
Can't Wait Until 2027-2028?
Retatrutide won't be available for 1-2 years. These FDA-approved GLP-1 medications use similar science and are available today.
Semaglutide & tirzepatide with licensed physicians. Includes medical consultation.
Compounded semaglutide & tirzepatide. Fast shipping, no hidden fees.
Trusted telehealth brand. GLP-1 prescriptions with ongoing clinical support.
*Pricing may vary. Requires medical consultation. We may earn a commission at no cost to you.
Latest Retatrutide Updates
FDA Approval Status: Phase 3 Results & Timeline
Latest on Eli Lilly's Phase 3 trials, FDA submission timeline, and expected 2027-2028 launch.
Retatrutide vs Tirzepatide: Head-to-Head
24% vs 22% weight loss—see the data on how retatrutide compares to Mounjaro/Zepbound.
Complete Safety Guide: Side Effects Explained
What to expect: nausea rates, dysesthesia risk, heart rate effects, and safety profile.
Stay Updated on Retatrutide
Join the waitlist for FDA approval updates, pricing info, and early access when it launches.